These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 32387022)
1. Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report. Phadke G; Kaushal A; Tolan DR; Hahn K; Jensen T; Bjornstad P; Roncal-Jimenez C; Hernando AA; Lanaspa MA; Alexander MP; Kukla A; Johnson RJ Am J Kidney Dis; 2020 Jul; 76(1):144-147. PubMed ID: 32387022 [TBL] [Abstract][Full Text] [Related]
2. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study. Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161 [TBL] [Abstract][Full Text] [Related]
3. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Chu C; Lu YP; Yin L; Hocher B Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483 [TBL] [Abstract][Full Text] [Related]
4. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors. Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129 [TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781 [TBL] [Abstract][Full Text] [Related]
8. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus. Elbeddini A; Gallinger J; Davey M; Brassard S; Gazarin M; Plourde F; Aly A Am J Case Rep; 2020 Feb; 21():e920115. PubMed ID: 32089542 [TBL] [Abstract][Full Text] [Related]
9. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor. Konta Y; Saito E; Sato K; Furuta K; Miyauchi K; Furukawa A; Sato H; Yamamoto T Intern Med; 2022 Nov; 61(21):3239-3243. PubMed ID: 35283386 [TBL] [Abstract][Full Text] [Related]
10. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation]. Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123 [No Abstract] [Full Text] [Related]
11. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031 [TBL] [Abstract][Full Text] [Related]
12. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT. Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352 [TBL] [Abstract][Full Text] [Related]
13. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. Menne J; Dumann E; Haller H; Schmidt BMW PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931 [TBL] [Abstract][Full Text] [Related]
14. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972 [TBL] [Abstract][Full Text] [Related]
15. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Saly DL; Perazella MA Am J Physiol Renal Physiol; 2017 Oct; 313(4):F951-F954. PubMed ID: 28637789 [TBL] [Abstract][Full Text] [Related]
16. Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury? Copur S; Yildiz A; Basile C; Tuttle KR; Kanbay M J Nephrol; 2023 Jan; 36(1):31-43. PubMed ID: 35962863 [TBL] [Abstract][Full Text] [Related]
17. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Dickenmann M; Oettl T; Mihatsch MJ Am J Kidney Dis; 2008 Mar; 51(3):491-503. PubMed ID: 18295066 [TBL] [Abstract][Full Text] [Related]
18. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Reed JW Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054 [TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838 [TBL] [Abstract][Full Text] [Related]
20. Acute Renal Failure With Cocaine and SGLT-2 Inhibitor. Shrivastava S; Srivastava N; Alfanso-Jaume M Am J Ther; 2019; 26(6):e762-e763. PubMed ID: 31425163 [No Abstract] [Full Text] [Related] [Next] [New Search]